These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17643193)

  • 1. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007).
    Matern D; Tortorelli S; Oglesbee D; Gavrilov D; Rinaldo P
    J Inherit Metab Dis; 2007 Aug; 30(4):585-92. PubMed ID: 17643193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
    Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
    J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.
    Minutti CZ; Lacey JM; Magera MJ; Hahn SH; McCann M; Schulze A; Cheillan D; Dorche C; Chace DH; Lymp JF; Zimmerman D; Rinaldo P; Matern D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3687-93. PubMed ID: 15292289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for remethylation disorders and vitamin B
    Gramer G; Abdoh G; Ben-Omran T; Shahbeck N; Ali R; Mahmoud L; Fang-Hoffmann J; Hoffmann GF; Al Rifai H; Okun JG
    World J Pediatr; 2017 Apr; 13(2):136-143. PubMed ID: 28101774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
    Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD).
    Oglesbee D; Sanders KA; Lacey JM; Magera MJ; Casetta B; Strauss KA; Tortorelli S; Rinaldo P; Matern D
    Clin Chem; 2008 Mar; 54(3):542-9. PubMed ID: 18178665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening.
    Monostori P; Szabó P; Marginean O; Bereczki C; Karg E
    Horm Res Paediatr; 2015; 84(5):311-8. PubMed ID: 26397944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birth Weight- or Gestational Age-adjusted Second-tier LCMSMS Cutoffs Improve Newborn Screening for CAH in New Zealand.
    de Hora MR; Heather NL; Webster D; Albert BB; Hofman PL
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3390-e3399. PubMed ID: 34058748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening: the role of the obstetrician.
    Larsson A; Therrell BL
    Clin Obstet Gynecol; 2002 Sep; 45(3):697-710; discussion 730-2. PubMed ID: 12370609
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of Principal Component Analysis to Newborn Screening for Congenital Adrenal Hyperplasia.
    Lasarev MR; Bialk ER; Allen DB; Held PK
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32525982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem spectrometry in newborn screening.
    Seashore MR
    Curr Opin Pediatr; 1998 Dec; 10(6):609-14. PubMed ID: 9848021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry.
    Chace DH; Hillman SL; Millington DS; Kahler SG; Roe CR; Naylor EW
    Clin Chem; 1995 Jan; 41(1):62-8. PubMed ID: 7813082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
    Kopacek C; de Castro SM; Prado MJ; da Silva CM; Beltrão LA; Spritzer PM
    BMC Pediatr; 2017 Jan; 17(1):22. PubMed ID: 28095810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants.
    Sarafoglou K; Gaviglio A; Hietala A; Frogner G; Banks K; McCann M; Thomas W
    J Pediatr; 2014 May; 164(5):1136-40. PubMed ID: 24582106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
    Fingerhut R
    Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in neonatal screening.
    Naylor EW
    Semin Perinatol; 1985 Apr; 9(3):232-49. PubMed ID: 3832439
    [No Abstract]   [Full Text] [Related]  

  • 17. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
    Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal screening: identification of children with 11β-hydroxylase deficiency by second-tier testing.
    Janzen N; Riepe FG; Peter M; Sander S; Steuerwald U; Korsch E; Krull F; Müller HL; Heger S; Brack C; Sander J
    Horm Res Paediatr; 2012; 77(3):195-9. PubMed ID: 22508345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience.
    Schwarz E; Liu A; Randall H; Haslip C; Keune F; Murray M; Longo N; Pasquali M
    Pediatr Res; 2009 Aug; 66(2):230-5. PubMed ID: 19390483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms.
    Puckett RL; Lorey F; Rinaldo P; Lipson MH; Matern D; Sowa ME; Levine S; Chang R; Wang RY; Abdenur JE
    Mol Genet Metab; 2010 Jun; 100(2):136-42. PubMed ID: 20307994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.